Information Provided By:
Fly News Breaks for March 12, 2018
Mar 12, 2018 | 10:52 EDT
As previously reported, Piper Jaffray analyst Edward Tenthoff double downgraded Anthera to Underweight from Overweight after the company's Phase 3 trial of Sollpura missed the primary non-inferiority endpoint of Coefficient of Fat Absorption in patients with cystic fibrosis with exocrine pancreatic insufficiency, or CF-EPI. Tenthoff, who expects Anthera will further reduce headcount in order to focus on strategic alternatives, cut his price target on Anthera shares to 10c from $4 based on his value for blisibimod of $5M, less the company's net debt. In morning trading, Anthera has plunged 80% to 52c per share.
News For ANTH From the Last 2 Days
There are no results for your query ANTH
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.